{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:21:06Z","timestamp":1790706066706,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/sj.bdj.2017.1039","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T05:40:46Z","timestamp":1513316446000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["MRONJ risk of adjuvant bisphosphonates in early stage breast cancer"],"prefix":"10.1038","volume":"224","author":[{"given":"V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nizarali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"BFsjbdj20171039_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014; 72: 1938\u20131956.","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsjbdj20171039_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","volume":"219","author":"V Patel","year":"2015","unstructured":"Patel V, Kelleher M, Sproat C, Kwok J, and McGurk M . New cancer therapies and jaw necrosis. Br Dent J 2015; 219: 203\u2013207.","journal-title":"Br Dent J"},{"key":"BFsjbdj20171039_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen L S, Gordon D, Tchekmedyian S et al. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumours: A Phase III, Double-Blind, Randomized Trial \u2013 The Zoledronic Acid Lung Cancer and Other Solid Tumours Study Group. J Clin Oncol 2003; 21: 150\u2013157.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson J R, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593\u2013602.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR5","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman R E . Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clinical Cancer Research 2006; 12: 6243s\u20136249s.","journal-title":"Clinical Cancer Research"},{"key":"BFsjbdj20171039_CR6","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"BFsjbdj20171039_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman R E, Wilson C et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016; 27: 379\u2013390.","journal-title":"Ann Oncol"},{"key":"BFsjbdj20171039_CR8","unstructured":"Breast Cancer Now. Lay summary of adjuvant bisphosphonates financial modelling. Breast Cancer Now, 2016."},{"key":"BFsjbdj20171039_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AH Paterson","year":"2012","unstructured":"Paterson A H, Anderson S J, Lembersky B C et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734\u2013742.","journal-title":"Lancet Oncol"},{"key":"BFsjbdj20171039_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2013.31.15_suppl.3","volume":"31","author":"G von Minckwitz","year":"2013","unstructured":"von Minckwitz G, Mobus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3, 531\u2013539.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1200\/jco.2015.33.15_suppl.503","volume":"33","author":"J Gralow","year":"2015","unstructured":"Gralow J, Barlow W E, Paterson A H G et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology study S0307. J Clin Oncol 2015; 33: abstract 503.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313\u2013320.","journal-title":"Ann Oncol"},{"key":"BFsjbdj20171039_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398\u2013405.","journal-title":"Ann Oncol"},{"key":"BFsjbdj20171039_CR14","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","volume":"31","author":"EJ Rathbone","year":"2013","unstructured":"Rathbone E J, Brown J E, Marshall H C et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04). J Clin Oncol 2013; 31: 2685\u20132691.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O'Ryan F S, Gordon N P et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. J Oral Maxillofac Surg 2010; 68: 243\u2013253.","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsjbdj20171039_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00774-011-0299-z","volume":"30","author":"N Malden","year":"2012","unstructured":"Malden N, Lopes V . An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab 2012; 30: 171\u2013182.","journal-title":"J Bone Miner Metab"},{"key":"BFsjbdj20171039_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan A A, Morrison A, Hanley D A et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Min Res 2015; 30: 3\u201323.","journal-title":"J Bone Min Res"},{"key":"BFsjbdj20171039_CR18","unstructured":"Cancer Research UK. Breast cancer statistics. Available at http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer (accessed October 2017)."},{"key":"BFsjbdj20171039_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bdj.2017.121","volume":"222","author":"V Patel","year":"2017","unstructured":"Patel V, Ormondroyd L, Lyons A, and McGurk M . The financial burden for the surgical management of osteoradionecrosis. Br Dent J 2017; 222: 177\u2013180.","journal-title":"Br Dent J"},{"key":"BFsjbdj20171039_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti C I, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137\u2013145.","journal-title":"Ann Oncol"},{"key":"BFsjbdj20171039_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos M A, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117\u2013120.","journal-title":"Ann Oncol"},{"key":"BFsjbdj20171039_CR22","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1080\/10428190802483778","volume":"49","author":"V Montefusco","year":"2008","unstructured":"Montefusco V, Gay F, Spina F et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49: 2156\u20132162.","journal-title":"Leuk Lymphoma"},{"key":"BFsjbdj20171039_CR23","unstructured":"AAE Special Committee on Bisphosphonates Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws. American Association of Endodontists Position Paper. 2010. Available online at https:\/\/www.aae.org\/uploadedfiles\/clinical_resources\/guidelines_and_position_statements\/bisphosonatesstatement.pdf (accessed October 2017)."},{"key":"BFsjbdj20171039_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bjoms.2014.02.016","volume":"52","author":"V Patel","year":"2014","unstructured":"Patel V, Sproat C, Kwok J, Beneng K, Thavaraj S, and McGurk M . Histological evaluation of mandibular third molar roots retrieved after coronectomy. Br J Oral Maxillofac Surg 2014; 52: 415\u2013419.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"4","key":"BFsjbdj20171039_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ors.12262","volume":"10","author":"V. Patel","year":"2017","unstructured":"V. Patel D. Patel M. McGurk C. Sproat and J. Kwok . Flapless piezoelectric surgery in the management of jaw necrosis \u2013 a case series. Oral Surg 2017; DOI:10.1111\/ors.12262.","journal-title":"Oral Surgery"},{"key":"BFsjbdj20171039_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman S L, Schousboe J T, Gold D T . Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 2011; 22: 21\u201326.","journal-title":"Osteoporos Int"},{"key":"BFsjbdj20171039_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/jco.2014.32.15_suppl.558","volume":"32","author":"J Gralow","year":"2014","unstructured":"Gralow J, Barlow W E, Paterson A H G et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol 2014; 32: 558.","journal-title":"J Clin Oncol"},{"key":"BFsjbdj20171039_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CHV Poznak","year":"2011","unstructured":"Poznak C H V, Temin S, Yee G C et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221\u20131227.","journal-title":"J Clin Oncol"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2017.1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2017.1039","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/sj.bdj.2017.1039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2017.1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T23:07:10Z","timestamp":1684624030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/sj.bdj.2017.1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFsjbdj20171039"],"URL":"https:\/\/doi.org\/10.1038\/sj.bdj.2017.1039","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]},"assertion":[{"value":"18 September 2017","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}